Media coverage about Incyte (NASDAQ:INCY) has been trending positive on Wednesday, Accern Sentiment Analysis reports. The research group rates the sentiment of media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Incyte earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave news stories about the biopharmaceutical company an impact score of 45.930567413561 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s analysis:
- Taking a Look at the Data Behind: Incyte Corporation, (NASDAQ: INCY),Ironwood Pharmaceuticals, Inc., (NASDAQ … – Hot Stocks In Focus (press release) (reagentsglobalmarket.com)
- Incyte (INCY) Now Covered by Deutsche Bank (americanbankingnews.com)
- Incyte (INCY) Earns Buy Rating from Raymond James Financial (americanbankingnews.com)
- These stock’s have rarely let down their investors: Incyte Corporation, (NASDAQ: INCY), L Brands, Inc., (NYSE: LB … – Stocks In The News (press release) (tradingnewsnow.com)
- Incyte Corporation (INCY) return on assets -8.50% underperforms Healthcare sector – Morning Outlook (morningoutlook.com)
A number of equities analysts recently weighed in on INCY shares. J P Morgan Chase & Co restated a “buy” rating and set a $149.00 target price on shares of Incyte in a report on Thursday, August 31st. BMO Capital Markets restated an “outperform” rating and set a $172.00 target price on shares of Incyte in a report on Monday, August 28th. Jefferies Group restated a “buy” rating on shares of Incyte in a report on Friday, October 6th. Goldman Sachs Group started coverage on shares of Incyte in a report on Friday, October 6th. They set a “buy” rating and a $160.00 target price on the stock. Finally, Raymond James Financial upgraded shares of Incyte from a “market perform” rating to an “outperform” rating and set a $159.00 target price on the stock in a report on Monday, September 11th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $143.84.
Incyte (NASDAQ:INCY) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.06 by $0.11. The company had revenue of $381.50 million during the quarter, compared to analysts’ expectations of $360.34 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. Incyte’s quarterly revenue was up 41.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.19 earnings per share. analysts anticipate that Incyte will post -1.33 earnings per share for the current year.
In related news, EVP Reid M. Huber sold 696 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $98.01, for a total transaction of $68,214.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Barry P. Flannelly sold 714 shares of the company’s stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $124.25, for a total transaction of $88,714.50. Following the sale, the executive vice president now directly owns 15,496 shares of the company’s stock, valued at approximately $1,925,378. The disclosure for this sale can be found here. In the last three months, insiders sold 104,334 shares of company stock valued at $11,992,011. 17.70% of the stock is currently owned by company insiders.
Incyte Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.